The identification of human tumor suppressor genes has led to new insights into the mechanisms of human cancer development. Some of the first tumor suppressor genes were identified through studies of pediatric malignancies including the RB and WTI genes. In the case of Wilms' tumors, further investigations have led to the discovery of other potential tumor suppressor genes on chromosomes 11, 16 as well as an unmapped familial form. In a complementary fashion, he has taken a functional approach by using a biological assay, tumor suppression, to map the locations of functional tumor suppressor genes via monochromosome transfer. He has now narrowed the location of a second Wilms' tumor suppressor gene, WT2, to an approximately 350 kb region on 11p15.5. Other studies have placed translocations in Beckwith-Weidemann Syndrome patients and loss of heterozygosity for Wilms tumor samples in this same region. In addition, this region of the human genome contains genes subject to inactivation by genomic imprinting. Intriguingly, many Wilms' tumors show a loss of imprinting for genes in 11p15.5 leading to either their inactivation or increased expression. The role of these epigenetic events such as imprinting in Wilms' tumor and other human cancer development remains unknown. Therefore, the isolation and characterization of the WT2 tumor suppressor gene would constitute a major advance in understanding these influences. During the last funding period, he developed a PAC/BAC/PI contig across the WT2 tumor suppressor gene region and began the identification of candidate genes in the area. In this competitive renewal application, he proposes to isolate the WT2 gene and characterize its status in the development of Wilms' tumor.
In Specific Aim A, he will identify as many genes as possible for the WT2 tumor suppressor region by solution hybrid capture and analysis of genomic DNA sequence.
In Specific Aim B, he will screen each candidate gene for correlative expression with tumor suppression in a microcell hybrid model system. He also will search for genomic alterations in primary tumor samples and examine the expression pattern in normal tissues. He hopes to limit the number of strong candidate genes by these criteria to five or less. In the last specific aim, he will identify the WT2 gene by screening for mutations and loss of expression in primary tumor samples. He will also transfer the gene into the G401 cell line to demonstrate functional tumor suppressor activity. The availability of the WT2 gene will broaden the understanding of tumor suppressor gene functions, provide important clues about the process of normal mammalian tissue development including genomic imprinting and impact upon treatment and detection of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA063176-04
Application #
2008484
Study Section
Pathology B Study Section (PTHB)
Project Start
1994-06-01
Project End
2002-03-31
Budget Start
1997-06-01
Budget End
1998-03-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Rorie, Checo J; Weissman, Bernard E (2004) The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines. Cancer Res 64:7288-95
Rorie, Checo J; Thomas, Venetia D; Chen, Pengchin et al. (2004) The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 64:1266-77
Reisman, David N; Strobeck, Matthew W; Betz, Bryan L et al. (2002) Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 21:1196-207
Strobeck, Matthew W; Reisman, David N; Gunawardena, Ranjaka W et al. (2002) Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem 277:4782-9
Ricketts, Sharon L; Garcia, Nicole F; Betz, Bryan L et al. (2002) Identification of candidate liver tumor suppressor genes from human 11p11.2-p12. Genes Chromosomes Cancer 33:47-59
Xu, X L; Wu, L C; Du, F et al. (2001) Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res 61:7943-9
Decristofaro, M F; Betz, B L; Rorie, C J et al. (2001) Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 186:136-45
Strobeck, M W; Knudsen, K E; Fribourg, A F et al. (2000) BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci U S A 97:7748-53
Miele, M E; Jewett, M D; Goldberg, S F et al. (2000) A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int J Cancer 86:524-8
DeCristofaro, M F; Betz, B L; Wang, W et al. (1999) Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene 18:7559-65

Showing the most recent 10 out of 18 publications